Dosage form design for improvement of bioavailability of levodopa II: bioavailability of marketed levodopa preparations in dogs and parkinsonian patients.
To estimate the absolute bioavailability of oral levodopa, plasma concentrations and urinary excretion of levodopa and its metabolites were determined in beagle dogs and in parkinsonian patients after intravenous and oral drug administration. The absolute bioavailability of orally administered levodopa was estimated to be about 35% in both dogs and patients; however, the total amount absorbed of intact drug and levodopa metabolites was estimated to be 80--90% of the administered dose. Due to the similarities of the pharmacokinetic characteristics of levodopa found in beagle dogs and in humans, beagle dogs can serve as a model to study bioavailability, absorption, and metabolic mechanisms.
D000284:Administration, Oral; D000368:Aged; D000818:Animals; D001682:Biological Availability; D004285:Dogs; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007700:Kinetics; D007980:Levodopa / Q000008:administration & dosage* / Q000097:blood / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000378:metabolism*; D013045:Species Specificity
D007980:Levodopa